Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Teva
QuintilesIMS
Express Scripts
Covington
Julphar
McKinsey
Dow

Generated: October 22, 2018

DrugPatentWatch Database Preview

Loxapine succinate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for loxapine succinate and what is the scope of loxapine succinate freedom to operate?

Loxapine succinate is the generic ingredient in two branded drugs marketed by Elite Labs Inc, Lannett Co Inc, Mylan, Watson Labs, and Actavis Labs Ut Inc, and is included in eight NDAs. Additional information is available in the individual branded drug profile pages.

There are eight drug master file entries for loxapine succinate. Nine suppliers are listed for this compound.

Synonyms for loxapine succinate
13-CHLORO-10-(4-METHYLPIPERAZIN-1-YL)-2-OXA-9-AZATRICYCLO[9.4.0.0(3),?]PENTADECA-1(11),3(8),4,6,9,12,14-HEPTAENE; BUTANEDIOIC ACID
1977-10-2 (Parent)
2-Chloro-11-(4-methyl-1- piperazinyl)-dibenz[b,f][1,4]- oxazepine succinate
2-Chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine succinate (1:1)
2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine, Succinate
2-chloro-11-(4-methyl-1-piperazinyl)dibenzo[b,f][1,4]oxazepine succinate
27833-64-3
833L643
AC1L2G38
AC1Q5VQU
AKOS015994711
AOB5330
AZ-004
AZ-104
BIL2251
Butanedioic acid, compd. with 2-chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine (1:1)
Butanedioic acid, compd. with 2-chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine (1:1)
butanedioic acid; 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine
butanedioic acid;8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine
C-54162
C22H24ClN3O5
CAS-27833-64-3
CCG-39497
CCRIS 1917
CHEBI:6549
CHEMBL1201155
CL 71563
CL-71563
Cloxazepin
CPD000058470
CS-4285
CTK4G0318
D00794
Daxolin
DSSTox_CID_25227
DSSTox_GSID_45227
DSSTox_RID_80764
DTXSID3045227
EINECS 248-682-0
EU-0100720
FT-0653022
HMS1568K06
HMS1922L14
HMS2051E05
HMS2093N20
HMS2095K06
HMS2232N05
HMS3262O21
HMS3374F02
HMS3393E05
HMS3652O10
HY-17390A
KS-1083
Lederle
Lopac-L-106
Loxapac
Loxapine (succinate)
Loxapine succinate (USP)
Loxapine succinate [USAN:USP]
Loxapine succinate [USAN]
Loxapine succinate salt
Loxapine succinate salt, solid
Loxapine succinate, United States Pharmacopeia (USP) Reference Standard
Loxapine, Succinate
Loxapine,succinate
Loxapinesuccinatesalt
Loxipine Succinate
Loxitane (TN)
LP00720
LS-147408
MFCD00069298
MLS000069383
MLS000758291
MLS001146961
MLS001401432
MLS002222201
MolPort-003-666-776
NC00011
NCGC00016160-01
NCGC00016160-02
NCGC00016160-03
NCGC00016160-04
NCGC00016160-05
NCGC00021145-11
NCGC00094068-01
NCGC00094068-02
NCGC00094068-03
NCGC00261405-01
NSC-759578
NSC759578
O287
Opera_ID_1518
Pharmakon1600-02300242
PL001478
Prestwick_304
REGID_for_CID_71399
s4086
SAM001247061
SCHEMBL41643
SMR000058470
SPECTRUM2300242
Staccato-loxapine
Succinic acid, compd. with 2-chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine (1:1)
Succinic acid, compound with 2-chloro-11-(4-methylpiperazin-1-yl)dibenz(b,f)(1,4)oxazepine (1:1)
Tox21_110311
Tox21_110311_1
Tox21_500720
UNII-X59SG0MRYU
VA11204
VU0239541-8
W-107092
X59SG0MRYU
ZX-AFC001324

US Patents and Regulatory Information for loxapine succinate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan LOXAPINE SUCCINATE loxapine succinate CAPSULE;ORAL 076762-003 Nov 1, 2004 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Lannett Co Inc LOXAPINE SUCCINATE loxapine succinate CAPSULE;ORAL 090695-001 Sep 26, 2011 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Actavis Labs Ut Inc LOXITANE loxapine succinate CAPSULE;ORAL 017525-004 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Mylan LOXAPINE SUCCINATE loxapine succinate CAPSULE;ORAL 076762-002 Nov 1, 2004 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Actavis Labs Ut Inc LOXITANE loxapine succinate TABLET;ORAL 017525-008 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for loxapine succinate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Actavis Labs Ut Inc LOXITANE loxapine succinate CAPSULE;ORAL 017525-001 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Actavis Labs Ut Inc LOXITANE loxapine succinate CAPSULE;ORAL 017525-003 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Actavis Labs Ut Inc LOXITANE loxapine succinate CAPSULE;ORAL 017525-002 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Actavis Labs Ut Inc LOXITANE loxapine succinate CAPSULE;ORAL 017525-004 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Teva
QuintilesIMS
Express Scripts
Covington
Julphar
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.